STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Adult
Aged
Animals
Bile Acids and Salts
/ biosynthesis
Carcinoma, Hepatocellular
/ chemically induced
Cells, Cultured
Cohort Studies
Diet, High-Fat
/ adverse effects
Disease Models, Animal
Female
Gene Deletion
Hepatocytes
/ metabolism
Humans
Liver
/ pathology
Liver Neoplasms
/ chemically induced
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Mitochondria
/ metabolism
Non-alcoholic Fatty Liver Disease
/ chemically induced
Phosphoproteins
/ genetics
Signal Transduction
/ genetics
Young Adult
Bile acids
Cholesterol
Hepatocellular carcinoma
Mitochondria
Oxysterols
STARD1
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
19
06
2020
revised:
10
01
2021
accepted:
13
01
2021
pubmed:
31
1
2021
medline:
29
1
2022
entrez:
30
1
2021
Statut:
ppublish
Résumé
Besides their physiological role in bile formation and fat digestion, bile acids (BAs) synthesised from cholesterol in hepatocytes act as signalling molecules that modulate hepatocellular carcinoma (HCC). Trafficking of cholesterol to mitochondria through steroidogenic acute regulatory protein 1 (STARD1) is the rate-limiting step in the alternative pathway of BA generation, the physiological relevance of which is not well understood. Moreover, the specific contribution of the STARD1-dependent BA synthesis pathway to HCC has not been previously explored. STARD1 expression was analyzed in a cohort of human non-alcoholic steatohepatitis (NASH)-derived HCC specimens. Experimental NASH-driven HCC models included MUP-uPA mice fed a high-fat high-cholesterol (HFHC) diet and diethylnitrosamine (DEN) treatment in wild-type (WT) mice fed a HFHC diet. Molecular species of BAs and oxysterols were analyzed by mass spectrometry. Effects of NASH-derived BA profiles were investigated in tumour-initiated stem-like cells (TICs) and primary mouse hepatocytes (PMHs). Patients with NASH-associated HCC exhibited increased hepatic expression of STARD1 and an enhanced BA pool. Using NASH-driven HCC models, STARD1 overexpression in WT mice increased liver tumour multiplicity, whereas hepatocyte-specific STARD1 deletion (Stard1 The study reveals a previously unrecognised role of STARD1 in HCC pathogenesis, wherein it promotes the synthesis of primary BAs through the mitochondrial pathway, the products of which act in TICs to stimulate self-renewal, stemness and inflammation. Effective therapy for hepatocellular carcinoma (HCC) is limited because of our incomplete understanding of its pathogenesis. The contribution of the alternative pathway of bile acid (BA) synthesis to HCC development is unknown. We uncover a key role for steroidogenic acute regulatory protein 1 (STARD1) in non-alcoholic steatohepatitis-driven HCC, wherein it stimulates the generation of BAs in the mitochondrial acidic pathway, the products of which stimulate hepatocyte pluripotency and self-renewal, as well as inflammation.
Sections du résumé
BACKGROUND & AIMS
Besides their physiological role in bile formation and fat digestion, bile acids (BAs) synthesised from cholesterol in hepatocytes act as signalling molecules that modulate hepatocellular carcinoma (HCC). Trafficking of cholesterol to mitochondria through steroidogenic acute regulatory protein 1 (STARD1) is the rate-limiting step in the alternative pathway of BA generation, the physiological relevance of which is not well understood. Moreover, the specific contribution of the STARD1-dependent BA synthesis pathway to HCC has not been previously explored.
METHODS
STARD1 expression was analyzed in a cohort of human non-alcoholic steatohepatitis (NASH)-derived HCC specimens. Experimental NASH-driven HCC models included MUP-uPA mice fed a high-fat high-cholesterol (HFHC) diet and diethylnitrosamine (DEN) treatment in wild-type (WT) mice fed a HFHC diet. Molecular species of BAs and oxysterols were analyzed by mass spectrometry. Effects of NASH-derived BA profiles were investigated in tumour-initiated stem-like cells (TICs) and primary mouse hepatocytes (PMHs).
RESULTS
Patients with NASH-associated HCC exhibited increased hepatic expression of STARD1 and an enhanced BA pool. Using NASH-driven HCC models, STARD1 overexpression in WT mice increased liver tumour multiplicity, whereas hepatocyte-specific STARD1 deletion (Stard1
CONCLUSIONS
The study reveals a previously unrecognised role of STARD1 in HCC pathogenesis, wherein it promotes the synthesis of primary BAs through the mitochondrial pathway, the products of which act in TICs to stimulate self-renewal, stemness and inflammation.
LAY SUMMARY
Effective therapy for hepatocellular carcinoma (HCC) is limited because of our incomplete understanding of its pathogenesis. The contribution of the alternative pathway of bile acid (BA) synthesis to HCC development is unknown. We uncover a key role for steroidogenic acute regulatory protein 1 (STARD1) in non-alcoholic steatohepatitis-driven HCC, wherein it stimulates the generation of BAs in the mitochondrial acidic pathway, the products of which stimulate hepatocyte pluripotency and self-renewal, as well as inflammation.
Identifiants
pubmed: 33515644
pii: S0168-8278(21)00040-4
doi: 10.1016/j.jhep.2021.01.028
pmc: PMC8573791
mid: NIHMS1667239
pii:
doi:
Substances chimiques
Bile Acids and Salts
0
Phosphoproteins
0
steroidogenic acute regulatory protein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1429-1441Subventions
Organisme : NCI NIH HHS
ID : R01 CA211794
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA011999
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234128
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA022614
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA027681
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
J Exp Med. 2017 May 1;214(5):1387-1409
pubmed: 28356389
Redox Biol. 2018 Apr;14:164-177
pubmed: 28942194
Liver Res. 2019 May 21;3(2):88-98
pubmed: 32015930
Cell Metab. 2012 May 2;15(5):665-74
pubmed: 22560219
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Hepatology. 2004 Oct;40(4):910-7
pubmed: 15382124
Cell. 2010 Jan 22;140(2):197-208
pubmed: 20141834
Cell Mol Gastroenterol Hepatol. 2016 Dec 10;3(2):261-271
pubmed: 28275692
Gastroenterology. 2019 Aug;157(2):552-568
pubmed: 31029706
Am J Physiol Gastrointest Liver Physiol. 2016 Jul 1;311(1):G91-G104
pubmed: 27151938
Cell Metab. 2013 Feb 5;17(2):225-35
pubmed: 23395169
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Cancers (Basel). 2019 Oct 29;11(11):
pubmed: 31671735
Cell Death Differ. 2008 Mar;15(3):484-93
pubmed: 18084240
Aging (Albany NY). 2020 Jan 5;12(1):571-592
pubmed: 31902793
Cancer Sci. 2019 Feb;110(2):771-783
pubmed: 30520543
Cancer Lett. 2018 Aug 10;429:66-77
pubmed: 29746928
Lancet Oncol. 2002 Sep;3(9):565-74
pubmed: 12217794
Hepatology. 2019 May;69(5):2241-2257
pubmed: 30372785
Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Jan;1862(1):90-101
pubmed: 27565112
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Oncotarget. 2016 Apr 19;7(16):22948-59
pubmed: 27027345
Cell Metab. 2019 Jan 8;29(1):18-26
pubmed: 30449681
J Clin Invest. 2013 Jul;123(7):2832-49
pubmed: 23921128
Gastroenterology. 2020 May;158(6):1713-1727
pubmed: 31972238
Cancer Res. 2008 Jul 1;68(13):5246-56
pubmed: 18593925
Biochimie. 2014 Jan;96:85-95
pubmed: 24076129
Cell Rep. 2012 Sep 27;2(3):580-90
pubmed: 22981231
Nat Commun. 2018 Oct 26;9(1):4490
pubmed: 30367044
J Hepatol. 2009 Apr;50(4):789-96
pubmed: 19231010
Am J Pathol. 2000 Dec;157(6):1963-74
pubmed: 11106569
J Steroid Biochem Mol Biol. 2019 May;189:36-47
pubmed: 30710743
Biochem Biophys Res Commun. 2019 Feb 19;509(4):855-861
pubmed: 30638930
Hepatology. 2006 Aug;44(2):478-86
pubmed: 16871584
Redox Biol. 2019 Jun;24:101214
pubmed: 31108462
Int J Biol Markers. 2018 Nov;33(4):423-431
pubmed: 29874983
J Biol Chem. 2002 Dec 13;277(50):48158-64
pubmed: 12368294
Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):34-42
pubmed: 23147664
Mol Aspects Med. 2017 Aug;56:10-24
pubmed: 28322867
Nat Med. 2017 Jul;23(7):839-849
pubmed: 28604703
J Endocrinol. 2012 Mar;212(3):257-75
pubmed: 21965545
Stem Cells. 2009 Feb;27(2):290-9
pubmed: 19008348
Sci Transl Med. 2018 Apr 18;10(437):
pubmed: 29669855
Hepatology. 2009 Apr;49(4):1277-86
pubmed: 19115422
Cancer Cell. 2014 Sep 8;26(3):331-343
pubmed: 25132496
Biol Chem. 2019 Apr 24;400(5):625-628
pubmed: 30465713
Biochim Biophys Acta. 2010 Jul;1801(7):683-92
pubmed: 20399894
Carcinogenesis. 2007 May;28(5):940-6
pubmed: 17183066
Cell Metab. 2006 Sep;4(3):185-98
pubmed: 16950136
Cell. 2018 Sep 20;175(1):133-145.e15
pubmed: 30220454
Hepatology. 2018 Feb;67(2):534-548
pubmed: 28696585
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Hepatology. 2015 Apr;61(4):1239-50
pubmed: 25482832
Stem Cells Dev. 2019 Jul 15;28(14):907-919
pubmed: 31122128
Clin Transl Med. 2016 Dec;5(1):22
pubmed: 27455839
Cancer Res. 2007 Feb 1;67(3):863-7
pubmed: 17283114
Annu Rev Cell Dev Biol. 2007;23:675-99
pubmed: 17645413
J Mol Biol. 2008 Sep 19;381(5):1168-83
pubmed: 18590739
Hepatology. 2017 Aug;66(2):416-431
pubmed: 28073164
Gut. 2020 Jan;69(1):177-186
pubmed: 30954949